A Phase I/IIa Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of SPN-812 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)

Trial Profile

A Phase I/IIa Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of SPN-812 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)

Completed
Phase of Trial: Phase I/II

Latest Information Update: 10 May 2017

At a glance

  • Drugs Viloxazine (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Therapeutic Use
  • Sponsors Supernus Pharmaceuticals
  • Most Recent Events

    • 18 Jun 2012 Additional lead trial investigator (Lowen M) identified as reported by ClinicalTrials.gov.
    • 11 Nov 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 11 Nov 2010 Actual end date (Oct 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top